Novel monoclonal antibody-based therapies for leukemia

Monoclonal Antibodies in Oncology

Volumn , Issue , 2013, Pages 55-77

  D'Cruz, Osmond J ^a,b   Uckun, Fatih M ^b,c  

^a Abraxis BioScience   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84956987179     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2217/EBO.13.218     Document Type: Chapter

References (93)

1. Hamann P, Hinman LM, Beyer CF et al. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug. Chem.13, 40-46 (2002).
2. Griffin JD, Linch D, Sabbath K et al. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk. Res. 8, 521-534 (1984).
3. Bross PF, Beitz J, Chen G et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490-1496 (2001).
4. Larson RA, Sievers EL, Stadtmauer EA et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg(r)) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104, 1442-1452 (2005).
5. Burnett AK, Hills RK, Milligan D et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J. Clin. Oncol. 29, 369-377 (2011).
6. Burnett AK, Russell NH, Hills RK et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J. Clin. Oncol. 30, 3924-3931 (2012).
7. Petersdorf S, Kopecky K, Stuart RK et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup Phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 114(22), 790 (2009).
8. Castaigne S, Pautas C, Terre C et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, Phase 3 study. Lancet 379, 1508-1516 (2012).
9. Latagliata R, Petti MC, Fenu S et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood 99, 822-824 (2002).
10. Breccia M, Cimino G, Diverio D et al. Sustained molecular remission after low dose gemtuzumab ozogamicin in elderly patients with advanced acute promyelocytic leukemia. Haematologica 92, 1273-1274 (2007).
11. Ravandi F, Estey E, Jones D et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J. Clin. Oncol. 27, 504-510 (2009).
12. Uckun FM, Jaszcz W, Ambrus JL et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71, 13-29 (1988).
13. Uckun FM. Regulation of human B-cell ontogeny. Blood 76, 1723-1733 (1990).
14. Uckun FM, Burkhardt AL, Jarvis L et al. Signal transduction through the CD19 receptor during discrete developmental stages of human B-cell ontogeny. J. Biol. Chem. 268, 21172-21184 (1993).
15. Hooijberg E, van den Berk PC, Sein JJ et al. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model. Cancer Res. 55, 840-846 (1995).
16. Shah SA, Halloran PM, Ferris CA et al. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res. 53, 1360-1367 (1993).
17. Kreitman RJ. Toxin-labeled monoclonal antibodies. Curr. Pharm. Biotechnol. 2, 313-325 (2001).
18. Grossbard ML, Lambert JM, Goldmacher VS et al. Anti-B4-blocked ricin: a Phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J. Clin. Oncol. 11, 726-737 (1993).
19. Grossbard ML, Freedman AS, Ritz J et al. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a Phase I trial of daily bolus infusion. Blood 79, 576-585 (1992).
20. Nourse J, Mellentin JD, Galili N et al. Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor. Cell 60, 535-545 (1990).
21. Hoffmann P, Hofmeister R, Brischwein K et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int. J. Cancer 115, 98-104 (2005).
22. Dreier T, Baeuerle PA, Fichtner I et al. T cell costimulusindependent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J. Immunol. 170, 4397-4402 (2003).
23. Schlereth B, Quadt C, Dreier T et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol. Immunother. 55, 503-514 (2006).
24. Bargou R, Leo E, Zugmaier G et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974-977 (2008).
25. Topp MS, Kufer P, Gökbuget N et al. Targeted therapy with the T cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29, 2493-2498 (2011).
26. Topp MS, Gokbuget N, Zugmaier G et al. Long-term follow-up of hematological relapse-free survival in a Phase 2 study of blinatumomab in patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (ALL). Blood 120, 5185-5187 (2012).
27. Topp MS, Gökbuget N, Zugmaier G et al. Anti-CD19 BiTE blinatumomab induces high complete remissione rate and prolongues survival in adult patients with relapsed/refractory B-precursore acute lymphoblastic leukemia (ALL). Hematologica 97(Suppl. 1), 462 (2012).
28. Gokbugel N, Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann. Hematol. 85, 201-205 (2004).
29. Maloney DG. Mechanism of action of rituximab. Anticancer Drugs 12(Suppl. 2), S1-S4 (2001).
30. Keating MJ, O'Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4079-4088 (2005).
31. Tam CS, O'Brien S, Wierda W et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112, 975-980 (2008).
32. Dworzak MN, Schumich A, Printz D et al. CD20 upregulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood 112, 3982-3988 (2008).
33. Thomas DA, Kantarjian H, Faderl S et al. Outcome after frontline therapy with the modified hyper-CVAD regimen with or without rituximab for de novo acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL). Blood 112, Abstract 1931 (2008).
34. Kantarjian H, Thomas D, O'Brien S et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101, 2788-2801 (2004).
35. Thomas DA, O'Brien S, Faderl S et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J. Clin. Oncol. 28, 3880-3889 (2010).
36. Leonard JP, Goldenberg DM. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 26, 3704-3713 (2007).
37. Raetz EA, Cairo MS, Borowitz MJ et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J. Clin. Oncol. 26, 3756-3762 (2008).
38. Herrera L, Bostrom B, Gore L et al. A Phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 31, 936-941 (2009).
39. Wayne AS, Kreitman RJ, Findley HW et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and Phase I clinical trial. Clin. Cancer Res. 16, 1894-1903 (2010).
40. Du X, Beers R, Fitzgerald DJ, Pastan I. Differential cellular internalization of anti-CD19 and-CD22 immunotoxins results in different cytotoxic activity. Cancer Res. 68, 6300-6305 (2008).
41. DiJoseph JF, Dougher MM, Armellino DC et al. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzmab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukaemia. Leukemia 21, 2240-2245 (2007).
42. Jabbour E, O'Brien SM, Thomas DA et al. Finotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). J. Clin. Oncol. 29(Suppl.), Abstract 6507 (2011).
43. Kantarjian H, Thomas D, Jorgensen J et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukemia: a Phase 2 study. Lancet Oncol. 13, 403-411 (2012).
44. Freeman SD, Kelm S, Barber EK, Crocker PR. Characterization of CD33 as a new member of the sialo adhesin family of cellular interaction molecules. Blood 85, 2005-2012 (1995).
45. Balduzzi A, Rossi V, Corral L et al. Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation. Leukemia 17, 2247-2248 (2003).
46. Golay J, Di Gaetano N, Amico D et al. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. Br. J. Hematol. 128, 310-317 (2005).
47. Zwaan CM, Reinhardt D, Jurgens H et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia 17, 468-470 (2003).
48. Cotter M, Rooney S, O'Marcaigh A, Smith OP. Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukemia. Br. J. Haematol. 122, 687-688 (2003).
49. Talpaz M, Kantarjian K, Freireich E et al. Phase I clinical trial of the anti-CD-33 immunotoxin HuM195/rGel [abstract]. Proceedings (American Association for Cancer Research) 44, 1228 (2003).
50. Chao MP, Alizadeh AA, Tang C et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 71, 1374-1384 (2011).
51. Tibes R, Keating MJ, Ferrajoli A et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 106, 2645-2651 (2006).
52. Laporte JP, Isnard F, Garderet L, Fouillard L, Gorin N-C. Remission of adult acute lymphocytic leukemia with alemtuzumab. Leukemia 18, 1557-1558 (2004).
53. Rodig SJ, Abramson JS, Pinkus GS et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin. Cancer Res. 12, 7174-7179 (2006).
54. Angiolillo AL, Yu AL, Reaman G, Ingle AM, Secola R, Adamson PC. A Phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatr. Blood Cancer 53, 978-983 (2009).
55. Liedtke M, Twist CJ, Mederiros BC et al. Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Hematologica 97, 30-37 (2012).
56. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111, 5446-5456 (2008).
57. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat. Rev. Cancer 10, 37-50 (2010).
58. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J. Clin. Oncol. 28, 3525-3530 (2010).
59. Osterborg A, Foa R, Bezares RF et al. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 23, 1980-1988 (2009).
60. Wierda WG, Kipps TJ, Mayer J et al. Ofatumumab as singleagent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 28, 1749-1755 (2010).
61. Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial. Lancet 376, 1164-1174 (2010).
62. Robak T, Dmoszynska A, Solal-Celigny P et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 28, 1756-1765 (2010).
63. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435-445 (1994).
64. Beum PV, Lindorfer MA, Beurskens F et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J. Immunol. 181, 822-832 (2008).
65. Golay J, Lazzari M, Facchinetti V et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98, 3383-3389 (2001).
66. Ladetto M, Bergui L, Ricca I, Campana S, Pileri A, Tarella C. Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients. Med. Oncol. 17, 203-210 (2000).
67. Huhn D, von Schilling C, Wilhelm M et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98, 1326-1331 (2001).
68. Itala M, Geisler CH, Kimby E et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur. J. Hematol. 69, 129-134 (2002).
69. Hainsworth JD, Litchy S, Barton JH et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a Phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 21, 1746-1751 (2003).
70. Thomas D, O'Brien S, Giles FJ et al. Single agent rituxan in early stage chronic lymphocytic leukemia (CLL). Blood 98, 364 (2001).
71. O'Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol. 19, 2165-2170 (2001).
72. Byrd JC, Murphy T, Howard RS et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol. 19, 2153-2164 (2001).
73. Byrd JC, Peterson BL, Morrison VA et al. Randomized Phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101, 6-14 (2003).
74. Schulz H, Klein SK, Rehwald U et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100, 3115-3120 (2002).
75. Wierda W, O'Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4070-4078 (2005).
76. Tam CS, O'Brien S, Wierda W et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112, 975-980 (2008).
77. Lamanna N, Kalaycio M, Maslak P et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 206(24), 1575-1581.
78. Kay NE, Geyer SM, Call TG et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109, 405-411 (2007).
79. Wierda WG, Kipps TJ, Mayer J et al. Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Blood 116, 921 (2010).
80. Wierda WG, Kipps TJ, Durig J et al. Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, Phase II trial. Blood 114, 207 (2009).
81. Mossner E, Brunker P, Moser S et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell mediated B-cell cytotoxicity. Blood 115, 4302-4393 (2010).
82. Morschhauser F, Cartron G, Lamy T et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Blood 114, Abstract 884 (2009).
83. Byrd JC, O'Brien S, Flinn IW et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin. Cancer Res. 13, 4448-4455 (2007).
84. van Spriel AB, Puls KL, Sofi M et al. A regulatory role for CD37 in T cell proliferation. J. Immunol. 172, 2953-2961 (2004).
85. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99, 3554-3561 (2002).
86. Osterborg A, Dyer MJ, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H treatment in chronic lymphocytic leukemia. J. Clin. Oncol. 15, 1567-1574 (1997).
87. Rai KR, Freter CE, Mercier RJ et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J. Clin. Oncol. 20, 3891-3897 (2002).
88. Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J. Clin. Oncol. 23, 2971-2979 (2005).
89. Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 25, 5616-5623 (2007).
90. Elter T, Borchmann P, Schulz H et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a Phase II trial. J. Clin. Oncol. 23, 7024-7031 (2005).
91. Wierda W, O'Brien S, Faderl S et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood 108, 14a (2006).
92. Faderl S, Thomas DA, O'Brien S et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101, 3413-3415 (2003).
93. American Cancer Society. Cancer Facts and Figures 2013. www.cancer.gov/ cancertopics/pdq/treatment/ adultAML/healthprofessional/page1.